Skip to main content

Golimumab Dosage

Medically reviewed by Drugs.com. Last updated on Jun 6, 2023.

Applies to the following strengths: 50 mg/0.5 mL; 100 mg/mL; 50 mg/4 mL

Usual Adult Dose for Psoriatic Arthritis

Subcutaneous: 50 mg once a month
IV: 2 mg/kg over 30 minutes at weeks 0 and 4, then every 8 weeks thereafter

Comments:


Uses: For the treatment of patients with active psoriatic arthritis (PsA)

Usual Adult Dose for Ulcerative Colitis

Initial dose: 200 mg subcutaneously at week 0, followed by 100 mg at week 2
Maintenance dose: 100 mg subcutaneously every 4 weeks

Comments:


Use: For the treatment of patients with moderate to severe ulcerative colitis (UC) who have demonstrated corticosteroid dependence or who have had an inadequate response to or failed to tolerate oral aminosalicylates, oral corticosteroids, azathioprine, or 6-mercaptopurine for:

Usual Adult Dose for Rheumatoid Arthritis

Subcutaneous: 50 mg once a month
IV: 2 mg/kg over 30 minutes at Weeks 0 and 4, then every 8 weeks thereafter

Comments:


Use: For the treatment of patients with moderately to severely active rheumatoid arthritis

Usual Adult Dose for Ankylosing Spondylitis

Subcutaneous: 50 mg once a month
IV: 2 mg/kg over 30 minutes at weeks 0 and 4, then every 8 weeks thereafter

Comments:


Use: For the treatment of patients with active ankylosing spondylitis (AS)

Usual Pediatric Dose for Psoriatic Arthritis

IV: 80 mg/m2 over 30 minutes at weeks 0 and 4, and every 8 weeks thereafter

Comments:


Use: For the treatment of active psoriatic arthritis in patients 2 years of age and older

Usual Pediatric Dose for Juvenile Idiopathic Arthritis

IV: 80 mg/m2 over 30 minutes at weeks 0 and 4, and every 8 weeks thereafter

Comments:


Use: For the treatment of active polyarticular juvenile idiopathic arthritis (pJIA) in patients 2 years of age and older

Renal Dose Adjustments

Data not available

Liver Dose Adjustments

Data not available

Precautions

US BOXED WARNINGS:

REPORTED INFECTIONS:

CONTRAINDICATIONS: None

Safety and effectiveness of the IV route for active polyarticular juvenile idiopathic arthritis and PsA have been established in pediatric patients 2 years and older.

Consult WARNINGS section for additional precautions.

Dialysis

Data not available

Other Comments

Administration advice:
SUBCUTANEOUS:

IV:

Storage requirements:

Reconstitution/preparation techniques:

Monitoring:

Patient advice:

Frequently asked questions

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.